Public Notices: Peak Powder River Resources, LLC (F031172/A0016113)
Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
01/26/2024 | Press release | Distributed by Public on 01/26/2024 08:24
Please select the service you want to use:
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact